XML 156 R20.htm IDEA: XBRL DOCUMENT
v3.25.0.1

License, Clinical Trial and Sponsored Research Agreements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2023
License agreements |
License, Clinical Trial and Sponsored Research Agreements |
Schedule of Clinical Trial and Sponsored Research Agreements | For the years ended December 31, 2023 and 2022, the Company recorded the following expense in research and development for licenses acquired: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31,
($ in thousands) |  | 2023 |  | 2022
City of Hope National Medical Center | ​ | ​ | ​ | ​ | ​ | ​
IV/ICV | ​ | ​ | — | ​ | ​ | 125
HER2 | ​ | ​ | — | ​ | ​ | 200
CSL Behring (Calimmune) | ​ | ​ | 50 | ​ | ​ | 40
Fortress Annual Stock Dividend | ​ | ​ | 477 | ​ | ​ | 1,109
Total | ​ | $ | 527 | ​ | $ | 1,474
Sponsored research and clinical trial agreements |
License, Clinical Trial and Sponsored Research Agreements |
Schedule of Clinical Trial and Sponsored Research Agreements | For the year ended December 31, 2023 and 2022, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the year ended December 31,
($ in thousands) | ​ | 2023 |  | 2022
City of Hope National Medical Center | ​ | ​ | ​ | ​ | ​ | ​
CD123 | ​ | $ | 23 | ​ | $ | 166
IL13Rα2 | ​ | ​ | 1,115 | ​ | ​ | 1,486
CS1 | ​ | ​ | 188 | ​ | ​ | 482
HER2 | ​ | ​ | — | ​ | ​ | 784
PSCA | ​ | ​ | 44 | ​ | ​ | 103
Fred Hutchinson Cancer Center - CD20 | ​ | ​ | 1,254 | ​ | ​ | 1,987
St. Jude Children’s Research Hospital - XSCID | ​ | ​ | 637 | ​ | ​ | 508
Leiden University Medical Center - RAG1 SCID | ​ | ​ | 350 | ​ | ​ | 505
Mayo Clinic | ​ | ​ | 551 | ​ | ​ | 968
Total | ​ | $ | 4,162 | ​ | $ | 6,989

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mbio_LicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=mbio_SponsoredResearchAndClinicalTrialAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |